Device Trial Radar · NCT01852084
Hydrophobic Acrylic Toric IOL Designed to Reduce the Effects of Preoperative Corneal Astigmatism
Last checked: Nov 19, 2026Latest source record: Sep 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
191
Actual
Start
Mar 6, 2013
Primary completion
Jul 18, 2016
Study completion Dec 2016
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedNot on our public-company list
- Sponsor type
- Industry
- First posted
- May 13, 2013
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigational enVista IOL, Model MX60Tis equipped with toric optics and axis marks on the posterior surface to minimize the possibility of surgically induced astigmatism.
Conditions
- Astigmatism
Interventions
enVista® One-Piece Hydrophobic Acrylic Toric IOLDevice
Test lens having a toric cylinder power of either 1.25 diopters (D), 2.00 D, or 2.75 D
enVista control lensDevice
Spherical Control lens
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Dioptric Change in CylinderTime frame: Baseline, Final Visit (scheduled within window: days 120-180)
- Percentage of Participants With Intraocular Lens (IOL) Rotation of Less Than or Equal to Five DegreesTime frame: Form 3 Visit (window: days 30-60), Final Visit (window: days 120-180)
- Mean Best-corrected Distance Visual Acuity (BCDVA) at Final VisitTime frame: Final Visit (scheduled within window: days 120-180)
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bausch & Lomb
Irvine, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.